IJR - iShares Core S&P Small-Cap ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
87.04
+0.67 (+0.78%)
At close: 4:00PM EDT

86.96 -0.08 (-0.09%)
After hours: 5:59PM EDT

Stock chart is not supported by your current browser
Previous Close86.37
Open86.40
Bid86.21 x 2200
Ask88.10 x 900
Day's Range86.02 - 87.08
52 Week Range66.77 - 87.14
Volume3,365,800
Avg. Volume3,380,211
Net Assets42.94B
NAV83.51
PE Ratio (TTM)N/A
Yield1.17%
YTD Return9.31%
Beta (3y)1.00
Expense Ratio (net)0.07%
Inception Date2000-05-22
Trade prices are not sourced from all markets
  • ETF Databaseyesterday

    This Week’s ETF Launches: AdvisorShares Partners with Dorsey Wright for New ETFs

    Dorsey Wright has been lending its investment expertise to ETF issuers for over a decade.

  • ETF Trends6 days ago

    5 Big Reasons Why Small-Cap ETFs Are Leading

    Small-cap stocks and the related small-cap ETFs, including the iShares Core S&P Small-Cap ETF (IJR) , which tracks the S&P Small-Cap 600 Index, are equity market leaders this year. Keeping the the small-cap’s momentum going, traders believed smaller companies were insulated from the overseas turmoil. “Small-cap companies tend to source a larger portion of their revenue domestically compared to large caps,” according to BlackRock. “As such, they pay an estimated corporate tax rate of around 32% vs. 28% for larger firms.

  • ETF Trends10 days ago

    Small-Cap ETFs Are Really Trouncing Large-Cap Rivals

    For example, the iShares Core S&P Small-Cap ETF (IJR) , which tracks the S&P Small-Cap 600 Index, surged last week, bringing its year-to-date gain to over 12%. Keeping the the small-cap’s momentum going, traders believed smaller companies were insulated from the overseas turmoil.

  • Investopedia21 days ago

    Top 3 Small-Cap ETFs for 2018

    There's a case to be made that small-cap ETFs will outperform in the months ahead. Here are a few to consider.

  • ETF Trends22 days ago

    The Best Small-Cap ETFs Leading Market’s Charge

    Small-Cap ETFs are leading the markets charge this year. Year-to-date, the iShares Core S&P Small-Cap ETF (NYSEArca: IJR), which tracks the S&P Small-Cap 600 Index, increased 10.9%; the iShares Russell ...

  • Investopedia24 days ago

    4 ETFs to Play the 2018 Small-Cap Boom

    Learn why small-cap stocks are outperforming in 2018. Discover four ETFs to add small-cap exposure to your portfolio.

  • ETF Trends28 days ago

    Small-Cap ETFs Big Winners in U.S., China Trade War

    While the U.S. and China are embroiled in an escalating trade war, small-cap stocks and small-cap ETFs are outperforming. Year-to-date, the iShares Core S&P Small-Cap ETF (IJR) , which tracks the S&P Small-Cap 600 Index, increased 13.2% and the iShares Russell 2000 ETF (IWM) , which tracks the benchmark Russell 2000 Index, gained 11.8% year-to-date while the S&P 500 was up 4.5%. Supporting the small-cap's recent run up, many traders believed smaller companies were insulated from the overseas turmoil.

  • Small-Cap ETF (IJR) Hits New 52-Week High
    Zacks29 days ago

    Small-Cap ETF (IJR) Hits New 52-Week High

    This small-cap ETF hits a new 52-week high. Are more gains in store for this ETF?

  • ETF Trendslast month

    Small-Cap ETFs’ Time to Shine

    The S&P SmallCap 600 Index has outperformed the benchmark S&P 500 Index of large-cap companies by 9.5% from February through May, marking an outperformance at the three-month premium level last seen since May 2002, according to a S&P Dow Jones Indices note. The SPDR S&P 600 Small Cap ETF (SLY), iShares Core S&P Small-Cap ETF (IJR) and Vanguard S&P Small-Cap 600 ETF (VIOO) , which all track the S&P SmallCap 600 Index, have increased 10.4% over the past three months, whereas the S&P 500 gained 2.6%. Jodie Gunzberg, Managing Director, Head of U.S. Equities, S&P Dow Jones Indices, pointed to a number of supporting factors that have helped small-caps outperform and may continue to bolster this market category ahead.

  • InvestorPlacelast month

    Buy These 7 Small-Cap Stocks for Their Emerging Opportunities

    Both the Russell 2000 and S&P 600 indices hit all-time highs last week as investors continued to jump on the small-cap bandwagon. Can anything stop small-cap stocks from moving higher over the remainder of 2018? A recession would halt them in their tracks, but barring the unthinkable, you might want to consider selling some of your large-cap holdings for small-cap stocks or exchange-traded funds because they’re hotter than a pistol.

  • ETF Trends2 months ago

    Small-Cap Party Could be Just Starting

    There is no doubt about it: small-cap stocks and the related exchange traded funds are in rally mode. The iShares Russell 2000 ETF (NYSEArca: IWM), which tracks the benchmark Russell 2000 Index, is up ...

  • Barrons.com2 months ago

    Energy ETFs Break Out on Higher Oil Prices

    Energy stocks are finding new life as oil prices climb and climb. Shares have been dead money for a while and seemed totally disconnected from crude prices, but investors have since come around. In a scan of more than 2,100 ETFs that closed last week at new highs relative to the MSCI All-Country World Index, energy ETFs "dominate" both on an absolute and relative basis, as Ned Davis Research Group's ETF strategist Will Geisdorf wrote in a report published Monday.

  • U.S. Equity Tops Last Week's Asset Flow
    Zacks4 months ago

    U.S. Equity Tops Last Week's Asset Flow

    The lure for U.S. equity ETFs returned with the record amount of inflows last week.

  • Analyzing Flotek Industries’ 4Q17 Performance by Segment
    Market Realist5 months ago

    Analyzing Flotek Industries’ 4Q17 Performance by Segment

    SLCA, FTK, and SPN: Did 4Q17 Earnings Impress Investors?

  • ETF Trends5 months ago

    Rising Interest Rates Does Not Spell Doom for Stock ETFs

    The Federal Reserve typically hikes interest rates to obviate an overheating economy during the later stages of an economic cycle, typically foreshadowing the eventual end of a bull market. Nevertheless, ...

  • Behind MiMedx Group’s Recent Financial Performance
    Market Realist5 months ago

    Behind MiMedx Group’s Recent Financial Performance

    Why Investors Are Eyeing MiMedx Group Today

  • Kiplinger6 months ago

    How to Cash In on Corporate Tax Cuts

    Investors can expect higher earnings and more generous dividends.

  • Investopedia6 months ago

    Top 3 Small-Cap ETFs for 2018

    There's a case to be made that small-cap ETFs will outperform in the months ahead. Here are a few to consider.

  • Analysts’ Ratings for Nektar Therapeutics in January 2018
    Market Realist6 months ago

    Analysts’ Ratings for Nektar Therapeutics in January 2018

    A Look at Nektar Therapeutics' Revenue Drivers in 2018Company overview

  • Investopedia8 months ago

    Top 3 Small-Cap ETFs for 2017

    There's a case to be made that small-cap ETFs will outperform in the final months of 2017. Here are a few to consider.

  • Investopedia9 months ago

    Small-Cap ETFs: Better Late Than Never?

    Small-cap stocks and ETFs are on a tear, but there are macro issues that could limit near-term upside.

  • ETF.com10 months ago

    Active Funds Suddenly Outperforming

    The latest SPIVA scorecard shows a large uptick in the number of actively managed funds that are outperforming their benchmarks.

  • Investopedia10 months ago

    A Big Battle Among Small-Cap ETFs

    One small-cap ETF has been king for a while, but the race for the crown is heating up.

  • ETF.com10 months ago

    Least Popular ETFs Of The Year

    It may be surprising to hear that in a year in which ETFs are shattering all sorts of records with regard to the amount of money they are taking in, the world's largest exchange-traded fund isn't participating in the bonanza. That's right; the SPDR S&P 500 ETF Trust (SPY), the $242 billion behemoth, has actually had net outflows this year to the tune of $4.2 billion.

  • Market Realist10 months ago

    Baxdela Is Expected to Boost Ligand Pharmaceuticals’ Revenues

    On June 19, 2017, Melinta Therapeutics announced that its drug, Baxdela, had secured regulatory approval from the FDA as a treatment option for adult patients suffering from acute bacterial skin and skin ...